Ensysce Biosciences
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $181 | $305 | $515 | $435 |
Gross Profit | -765 | 305 | -2,924 | -1,479 |
EBITDA | -1,955 | -1,842 | -3,163 | -2,700 |
EBIT | -1,955 | -3,685 | -6,319 | -5,407 |
Net Income | -1,967 | -3,116 | -3,504 | -2,689 |
Net Change In Cash | 181 | 305 | 515 | 435 |
Free Cash Flow | -2,309 | -3,408 | -1,801 | -2,262 |
Cash | 1,043 | 3,404 | 1,123 | 1,464 |
Basic Shares | 8,817 | 5,694 | 2,264 | 3,085 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $2,230 | $2,523 | $3,531 | $3,931 |
Gross Profit | -5,356 | -17,312 | 3,531 | 2,562 |
EBITDA | -10,718 | -24,222 | -19,870 | -1,613 |
EBIT | -10,718 | -24,222 | -19,870 | -1,613 |
Net Income | -10,613 | -24,961 | -29,145 | -938 |
Net Change In Cash | 2,230 | 2,523 | 3,531 | 3,931 |
Cost of Revenue | -1,011 | |||
Free Cash Flow | -10,779 | -17,887 | -8,242 | -1,247 |
Cash | 1,123 | 3,147 | 12,264 | 194 |
Basic Shares | 2,264 | 179 | 84 | 68 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.22 |
2024-03-31 | -$0.55 |
2023-12-31 | -$1.37 |
2023-09-30 | -$0.87 |
